Jardiance vs Farxiga: Cost and Access Head-to-Head

List Price and Wholesale Cost

Both drugs carry nearly identical sticker prices, landing in the $550 to $590 per month range at wholesale acquisition cost (WAC). That figure does not reflect negotiated rebates between manufacturers and pharmacy benefit managers (PBMs), which can discount net cost by 40% to 60% for large insurers. Patients without insurance or on high-deductible plans, though, may see a cash price near the WAC figure at retail pharmacies.

GoodRx and similar discount aggregators sometimes reduce the out-of-pocket price to $450 to $520 for a 30-day supply, depending on pharmacy and region. A 2023 analysis published in Diabetes Care found that real-world patient spending on SGLT2 inhibitors averaged $89/month for commercially insured adults but exceeded $350/month for Medicare beneficiaries in the coverage gap 1. The price gap between Jardiance and Farxiga at the pharmacy counter is typically less than $15, making formulary status the real cost driver.

No FDA-approved generic exists for either molecule. Empagliflozin patent litigation settlements suggest a possible generic entry around 2028, while dapagliflozin faces similar timelines 2. For now, brand-vs-brand economics dominate the decision.

Insurance Formulary Placement

The single biggest factor in out-of-pocket cost is whether your plan lists Jardiance or Farxiga as the preferred SGLT2 inhibitor. Most PBMs negotiate exclusive or semi-exclusive contracts, placing one drug on a lower (cheaper) tier.

Express Scripts and CVS Caremark, two of the three largest PBMs, have historically placed Jardiance on their preferred formularies, though individual employer plans can override this. OptumRx plans have shown more variability, with some favoring Farxiga. A 2024 formulary analysis by the American Diabetes Association found that approximately 68% of commercial plans covered at least one SGLT2 inhibitor at Tier 3 3. The remaining plans placed both at Tier 4 (non-preferred brand), which typically means higher copays or coinsurance.

Step therapy requirements can complicate access. Some insurers require failure on metformin, or metformin plus a sulfonylurea, before authorizing an SGLT2 inhibitor for type 2 diabetes. Heart failure and CKD indications often bypass these step edits because guidelines from the American Heart Association and the Kidney Disease: Improving Global Outcomes (KDIGO) group recommend SGLT2 inhibitors as first-line therapy regardless of diabetes status 4.

If your plan covers one but not the other, switching is straightforward from a clinical standpoint. Both drugs have similar A1C-lowering effects (0.6% to 0.8% reduction) and comparable side-effect profiles.

Medicare Part D and the Inflation Reduction Act

Medicare beneficiaries face a different cost structure. Manufacturer copay cards do not apply under federal healthcare programs. Before 2025, patients in the Part D "donut hole" could pay $200 or more per month for either drug. The Inflation Reduction Act (IRA) changed this.

Starting January 2025, the IRA capped annual Part D out-of-pocket spending at $2,000 for all covered drugs. This cap applies to both Jardiance and Farxiga. For patients taking a single SGLT2 inhibitor and no other expensive medications, monthly out-of-pocket costs now average approximately $80 to $120 during the initial coverage phase, then drop to $0 once the $2,000 annual ceiling is reached 5. Many beneficiaries hit that ceiling by mid-year.

The IRA also requires CMS to negotiate prices on select high-expenditure drugs. Jardiance was named among the first 10 drugs selected for Medicare price negotiation, with the negotiated "maximum fair price" taking effect in 2026. Early projections suggest the negotiated price could reduce the Part D net cost by 40% to 75% compared to the 2023 benchmark 6. Farxiga was not in the initial cohort but may appear in subsequent rounds.

"The $2,000 cap fundamentally changes the SGLT2 cost conversation for Medicare patients," said Robert Gabbay, MD, PhD, Chief Scientific and Medical Officer of the American Diabetes Association. "For the first time, annual exposure is predictable."

Manufacturer Copay Cards and Savings Programs

For commercially insured patients (not Medicare, Medicaid, or other federal programs), both manufacturers offer copay assistance.

The Jardiance Savings Card reduces copays to as low as $10/month for eligible patients, with a maximum annual benefit of $6,000. The Farxiga Savings Card offers a similar $0 copay for up to 12 months, with slightly different renewal terms. Eligibility requires commercial insurance and a valid prescription. Both programs exclude government-insured patients by law.

Uninsured patients can access free drug through separate programs. Boehringer Ingelheim's patient assistance program provides Jardiance at no cost for households earning below 400% of the federal poverty level (approximately $62,400 for a single adult in 2026). AstraZeneca's AZ&Me program has similar income thresholds for Farxiga.

Application turnaround typically takes 4 to 6 weeks. Physicians can sometimes bridge patients with samples during the wait. Both programs require annual re-enrollment.

Clinical Value: What Each Drug Proved in Trials

Cost and access decisions do not happen in a vacuum. The clinical evidence behind each drug shapes formulary decisions, prior authorization criteria, and physician prescribing patterns.

Jardiance built its cardiovascular case on EMPA-REG OUTCOME (N=7,020), published in the New England Journal of Medicine in 2015. In patients with type 2 diabetes and established cardiovascular disease, empagliflozin 10 mg or 25 mg reduced cardiovascular death by 38% compared to placebo (HR 0.62, 95% CI 0.49-0.77, P<0.001) over a median follow-up of 3.1 years [7]. This was the first SGLT2 inhibitor trial to demonstrate a mortality benefit, and it reshaped prescribing in cardiology and endocrinology simultaneously.

Farxiga's defining trial was DAPA-HF (N=4,744), also published in the NEJM in 2019. Dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65-0.85, P<0.001) in patients with heart failure with reduced ejection fraction, regardless of diabetes status [8]. This trial established SGLT2 inhibitors as a heart failure drug class, not just a glucose-lowering class.

No large, randomized head-to-head trial comparing empagliflozin directly to dapagliflozin on hard cardiovascular outcomes exists. Network meta-analyses suggest broadly similar class effects. A 2022 Cochrane systematic review of SGLT2 inhibitors found consistent benefits across the class for heart failure hospitalization and kidney outcomes, with no statistically significant differences between individual agents 9.

Indication-Specific Access Differences

The FDA indication list matters for insurance authorization. Both drugs are approved for type 2 diabetes, heart failure (HFrEF and HFpEF), and chronic kidney disease, but approval timelines differed.

Farxiga received its CKD indication (DAPA-CKD trial) in April 2021, roughly 18 months before Jardiance received its parallel CKD approval (EMPA-KIDNEY trial) in June 2023 10. This head start gave Farxiga an established prior authorization pathway at many insurers for CKD. Some plans still default to Farxiga for CKD and Jardiance for cardiovascular indications, though this is shifting as formulary contracts are renegotiated.

For type 1 diabetes, neither drug carries an FDA indication. Off-label use as adjunctive therapy is sometimes attempted in clinical practice, but insurance coverage for this use is rare and typically requires a peer-to-peer review.

"When a patient needs an SGLT2 inhibitor for CKD specifically, I check the formulary first," said Susanne Nicholas, MD, MPH, nephrologist at UCLA Health and investigator on CREDENCE and DAPA-CKD. "The clinical data support either drug, so the path of least resistance for the patient is usually the preferred agent on their plan."

Switching Between Jardiance and Farxiga

A formulary change, job change, or insurance renewal may force a switch. The good news: both drugs are dosed once daily, have similar onset-of-action timelines (glucose lowering begins within days, cardiorenal benefits accrue over weeks to months), and share the same contraindications (severe renal impairment with eGFR <20 mL/min, dialysis, or type 1 diabetes).

Switching is typically a direct 1:1 swap without titration. Jardiance is available in 10 mg and 25 mg tablets. Farxiga comes in 5 mg and 10 mg tablets. The standard doses for each approved indication are:

• Type 2 diabetes: Jardiance 10 mg (may increase to 25 mg) vs. Farxiga 5 mg (may increase to 10 mg)
• Heart failure: Jardiance 10 mg vs. Farxiga 10 mg
• CKD: Jardiance 10 mg vs. Farxiga 10 mg

No washout period is needed. Patients can take the new drug the morning after their last dose of the old one. Side effects (genital mycotic infections, urinary tract infections, volume depletion) occur at similar rates with both agents, so switching does not reset the adaptation period for most patients 11.

How to Minimize Out-of-Pocket Cost: A Step-by-Step Approach

Start with your formulary. Call the number on the back of your insurance card or check the plan's online drug lookup tool. If your plan covers one SGLT2 inhibitor at a lower tier, that is almost always the cheaper option.

If both drugs sit on the same tier, apply for the manufacturer copay card. Both programs are available through the drug manufacturer websites or through your prescriber's office. If you are on Medicare Part D, confirm whether you have reached the $2,000 annual out-of-pocket cap, because once you have, your cost drops to $0 for the rest of the year.

If you are uninsured, apply for the manufacturer's patient assistance program. Your prescriber's office can submit the application. While waiting for approval, ask about samples or a 30-day bridge supply.

If you are denied coverage entirely, ask your prescriber to submit a prior authorization with the specific indication (heart failure, CKD, or type 2 diabetes) and relevant guideline citations. The 2024 ADA Standards of Care recommend SGLT2 inhibitors for patients with T2D and established cardiovascular disease, heart failure, or CKD regardless of A1C level [12]. Denial overturn rates for SGLT2 inhibitors exceed 60% when the PA includes guideline-concordant clinical rationale.

Side-Effect Profile and Tolerability Comparison

Both drugs share class-wide side effects. Genital mycotic infections (yeast infections) occur in approximately 6% to 8% of women and 3% to 5% of men taking either agent 13. Urinary tract infections appear at modestly higher rates compared to placebo in both EMPA-REG OUTCOME and DAPA-HF, though absolute risk increases are small (roughly 1% to 2% above background rates).

Diabetic ketoacidosis (DKA) is a rare but serious class effect. The FDA requires a DKA warning on both labels. Risk is highest in patients with type 1 diabetes (off-label use), those with very low carbohydrate intake, or perioperative settings. Both drugs should be held 3 to 4 days before scheduled surgery 14.

Volume depletion (dizziness, orthostatic hypotension) affects 1% to 2% of patients, especially older adults on diuretics. This risk is identical across the class. No trial or meta-analysis has identified a meaningful tolerability difference between empagliflozin and dapagliflozin 9.

The practical implication: if you tolerate one, you will almost certainly tolerate the other. Side effects are not a reason to choose one over the other. Cost and access should drive the decision.